These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11349820)

  • 1. Effects of nonpeptide V1a and V2 antagonists on blood pressure fast oscillations in conscious rats.
    Japundzic-Zigon N
    Clin Exp Hypertens; 2001 May; 23(4):277-92. PubMed ID: 11349820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of nonpeptide and selective V1 and V2 antagonists on blood pressure short-term variability in spontaneously hypertensive rats.
    Japundzić-Zigon N; Milutinović S; Jovanović A
    J Pharmacol Sci; 2004 May; 95(1):47-55. PubMed ID: 15153650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of vasopressin on cardiovascular changes during hemorrhage in conscious rats.
    Fujisawa Y; Miyatake A; Hayashida Y; Aki Y; Kimura S; Tamaki T; Abe Y
    Am J Physiol; 1994 Nov; 267(5 Pt 2):H1713-8. PubMed ID: 7977803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
    Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
    Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats.
    Sampey DB; Burrell LM; Widdop RE
    Am J Physiol; 1999 Mar; 276(3):R872-9. PubMed ID: 10070150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of central vasopressin receptors in the modulation of autonomic cardiovascular controls: a spectral analysis study.
    Milutinović S; Murphy D; Japundzić-Zigon N
    Am J Physiol Regul Integr Comp Physiol; 2006 Dec; 291(6):R1579-91. PubMed ID: 17085750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic and selective vasopressin blockade in spontaneously hypertensive rats.
    Okada H; Suzuki H; Kanno Y; Yamamura Y; Saruta T
    Am J Physiol; 1994 Dec; 267(6 Pt 2):R1467-71. PubMed ID: 7810754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of vasopressin V1 and V2 receptor antagonists on the development of salt-induced hypertension in Dahl rats.
    Hashimoto J; Imai Y; Minami N; Munakata M; Abe K
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):548-54. PubMed ID: 8569214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of novel, nonpeptide vasopressin antagonists on progressive nephrosclerosis in rats.
    Okada H; Suzuki H; Kanno Y; Saruta T
    J Cardiovasc Pharmacol; 1995 May; 25(5):847-52. PubMed ID: 7630164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
    Nishikimi T; Kawano Y; Saito Y; Matsuoka H
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
    Nakamura T; Sakamaki T; Kurashina T; Hoshino J; Sato K; Ono Z; Murata K
    Life Sci; 1994; 55(4):PL67-72. PubMed ID: 8028441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
    Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Key amino acids of vasopressin V1a receptor responsible for the species difference in the affinity of OPC-21268.
    Shinoura H; Take H; Itoh S; Hirasawa A; Inoue K; Ohno Y; Hashimoto K; Tsujimoto G
    FEBS Lett; 2000 Jan; 466(2-3):255-8. PubMed ID: 10682838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
    Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced pressor response in spontaneously hypertensive rats induced by stimulation of vasopressin-V1 receptors.
    Yamauchi T; Ogura T; Oishi T; Harada K; Hashimoto M; Mimura Y; Asano N; Ota Z; Kageyama J
    Acta Med Okayama; 1995 Feb; 49(1):53-9. PubMed ID: 7762410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of V1- and V2-vasopressin (AVP) antagonists on the pressor, AVP and atrial natriuretic peptide responses to a hypertonic saline infusion in conscious anephric rats.
    Ota K; Kimura T; Inoue M; Funyu T; Shoji M; Sato K; Ohta M; Yamamoto T; Abe K
    Eur J Endocrinol; 1995 Jul; 133(1):127-32. PubMed ID: 7627334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.
    Naitoh M; Burrell LM; Risvanis J; Aldred KL; Rockell MD; Johnston CI; Phillips PA
    Am J Physiol; 1997 Feb; 272(2 Pt 2):F229-34. PubMed ID: 9124400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nonpeptide vasopressin receptor antagonists on developing, and established DOCA-salt hypertension in rats.
    Okada H; Suzuki H; Kanno Y; Saruta T
    Clin Exp Hypertens; 1995 Apr; 17(3):469-83. PubMed ID: 7613523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vascular responses to vasopressin antagonists in man and rat.
    Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
    Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
    Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
    Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.